Enadenotucirev

Content sourced from Wikipedia, licensed under CC BY-SA 3.0.

Enadenotucirev is an experimental virus designed to kill cancer cells. It is an engineered adenovirus, originally named ColoAd1. Researchers have added cancer-targeting genes using a tumor-specific immuno-gene therapy (T-SIGn) approach to create new cancer gene therapies.

In 2015, the European Medicines Agency granted orphan designation for ovarian cancer. Two early trials have finished: the EVOLVE and MOA studies. As of mid‑2019, two phase 1 trials were active: OCTAVE (ovarian cancer) and SPICE (multiple solid tumors). Another T-SIGn virus, NG-350A, is also in clinical testing.